Citations

Clear

391 citation(s) found for "Bi, Chun".

Normative Femoral and Tibial Lengths in a Modern Population of Twenty-First-Century U.S. Children
Chen, Chun‐Ho , Milbrandt, Todd A. , Babadi, Elham , Duong, Stephanie Q. , Larson, Dirk R. , Shaughnessy, William J. , Stans, Anthony A. , Hull, Nathan C. , Peterson, Hamlet A. , Larson, A. Noelle , Chen, Chunho , Larson, A Noelle , Larson, Dirk

Mayo Clinic

Journal of Bone and Joint Surgery | February 2, 2023 | Volume: 105 | Issue: 6 | Pages: 468-478

10.2106/jbjs.22.00690 | PMID 36727888 Get It

Background: The Green-Anderson (GA) leg-length data remain the gold standard for the age-based assessment of leg lengths in children despite their methodologic weaknesses. We aimed to summarize current growth trends among a cross-sectional cohort of modern U.S. children using quantile regression methods and to compare the median femoral and tibial lengths of the modern U.S. children with those of the GA cohort. Methods: A retrospective review of scanograms and upright slot-scanning radiographs obtained in otherwise healthy children between 2008 and 2020 was completed. A search of a radiology registry revealed 3,508 unique patients between the ages of 2 and 18 years for whom a standard-of-care scanogram or slot-scanning radiograph had been made. All patients with systemic illness, genetic conditions, or generalized diseases that may affect height were excluded. Measurements from a single leg at a single time point per subject were included, and the latest available time point was used for children who had multiple scanograms made. Quantile regression analysis was used to fit the lengths of the tibia and femur and overall leg length separately for male patients and female patients. Results: Seven hundred patients (328 female and 372 male) met the inclusion criteria. On average, the reported 50th percentile tibial lengths from the GA study at each time point were shorter than the lengths in this study by 2.2 cm (range, 1.4 to 3.3 cm) for boys and 2 cm (range, 1.1 to 3.1 cm) for girls. The reported 50th percentile femoral lengths from the GA study at each time point were shorter than the lengths in this study by 1.8 cm (range, 1.1 to 2.5 cm) for boys and 1.7 cm (range, 0.8 to 2.3 cm) shorter for girls. Conclusions: This study developed new growth charts for femoral and tibial lengths in a modern U.S. population of children. The new femoral and tibial lengths at nearly all time points are 1 to 3 cm longer than traditional GA data. The use of GA data for epiphysiodesis could result in underestimation of expected childhood growth. Level of Evidence: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Abstract TP19: Multicenter Experience With A Novel Cadasil Severity Grading System.
Anisetti, Bhrugun , Goldstein, Eric, Worrall, Bradford B. , Petrosian, Derek, Liu, Michael D, Stojadinovic, Eldina, Elahi, Fanny M. , Chiang, Chia‐Chun , Ross, Owen A. , Meschia, James F.

Mayo Clinic

Stroke | February 2, 2023 | Volume: 54 | Issue: Suppl_1 | Pages: No page available

10.1161/str.54.suppl_1.tp19 Get It

Introduction: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a genetic, progressive microangiopathy caused by mutations in the NOTCH3 gene. Patients often present with migraine and progressive subcortical infarcts resulting in vascular cognitive impairment and death. Currently, there are no disease modifying treatments. Limiting future trials is the lack of an objective construct to classify and monitor severity of disease. The purpose of this study was to gain experience with a novel CADASIL severity grading system. Methods: Neurologists at 5 academic centers retrospectively reviewed charts of those with confirmed CADASIL. Demographic and clinical data were recorded. The CADASIL severity grades were then assigned: 0 (asymptomatic), 1 (migraine alone), 2 (stroke or mild cognitive impairment), 3 (gait impairment or early dementia) and 4 (bedbound) based on available data. Standard descriptive statistical analyses were used. Results: We identified 138 patients; overall mean age of 50.9±13.1 years, 42.8% were men. 15 (10.9%) were grade 0, 50 (36.2%) were grade 1, 41 (44.2%) were grade 2, 12 (8.7%) were grade 3, and none were grade 4. Those with less severe disease tended to be younger, more likely men, had a lower rate of hypertension and diabetes mellitus and were less frequently tobacco users, Table 1. Increasing number of vascular risk factors was associated with higher severity grading. Conclusion: Our study highlights the ability of this severity scale to separate those with CADASIL into an ordinal system. As known in the literature, more advanced phenotypes of CADASIL tend to have more vascular risk factors. Future trials may consider utilizing this ordinal construct to monitor disease progression, response to therapy, or as a screening tool.
Narrative review of migraine management in patients with renal or hepatic disease
Stern, Jennifer I. , Datta, Shae , Chiang, Chia‐Chun , Garza, Ivan , Robertson, Carrie E. , Robertson, Carrie E , Chiang, Chia-Chun , Vieira, Dorice L.

Mayo Clinic

Headache: The Journal of Head and Face Pain | January 29, 2023 | Volume: 63 | Issue: 1 | Pages: 9-24

10.1111/head.14437 | PMID 36709407 Get It

Abstract Objectives/Background Treatment of migraine in the setting of either renal or hepatic disease can be daunting for clinicians. Not only does the method of metabolism have to be considered, but also the method of elimination/excretion of the parent drug and any active or toxic metabolites. Furthermore, it is difficult to think about liver or kidney disease in isolation, as liver disease can sometimes contribute to impaired renal function and renal disease can sometimes impair hepatic metabolism, through the cytochrome P450 system. Methods A detailed search for terms related to liver disease, renal disease, and migraine management was performed in PubMed, Ovid Medline, Embase, and the Cochrane Library.For each medication, product labels were retrieved and reviewed using the US FDA website, with additional review of IBM Micromedex, LiverTox, and the Renal Drug Handbook. Results This manuscript provides an overview of migraine drug metabolism and how it can be affected by liver and renal impairment. It reviews the standard terminology recommended by the US Food and Drug Administration for the different stages of hepatic and renal failure. The available evidence regarding the use of abortive and preventative medicines in the setting of organ failure is discussed in detail, including more recent therapies such as lasmiditan, gepants, and calcitonin gene‐related peptide antibodies. Conclusions For acute therapy, the use of NSAIDS should be limited, as these carry risk for both severe hepatic and renal disease. Triptans can be selectively used, often with dose guideline adjustments. Ubrogepant may be used in severe hepatic disease with dose adjustment and lasmiditan can be used in end stage renal disease. Though non‐medicine strategies may be the most reasonable initial approach, many preventative medications can be used in the setting of hepatic and renal disease, often with dose adjustment. This review provides tables of guidelines, including reduced dosing recommendations, for the use of abortive and preventative migraine medications in hepatic and renal failure.
Updates in pathology and molecular diagnostics to inform the evolving landscape of thoracic surgery and oncology
Sholl, Lynette M. , Naso, Julia , Sholl, Lynette , Lo, Ying‐Chun

Mayo Clinic

Journal of Surgical Oncology | January 11, 2023 | Volume: 127 | Issue: 2 | Pages: 244-257

10.1002/jso.27184 | PMID 36630101 Get It

AbstractThe pathologic assessment of lung cancers provides essential guidance to the surgeon and oncologist who are considering the best treatment strategies for patients with both early and advanced‐stage disease. The management of patients with lung cancer is predicated first and foremost on access to an accurate diagnosis, even when the sample size is limited, as is often the case with use of modern, minimally invasive sampling techniques. Once the diagnosis and disease stage are established, predictive biomarker testing may be essential, particularly for those patients with nonsmall cell lung carcinoma (NSCLC) being considered for immunotherapy or genomic biomarker‐driven targeted therapy. This review will discuss the best practices for the diagnosis of NSCLC using morphology and immunohistochemistry, thus providing the surgeon with needed information to understand and critically evaluate pathology reports. Controversial and evolving topics including tumor spread through airspaces, evaluation of multiple tumors, and staging based on invasive tumor size will be addressed. Clinical genomic profiling in NSCLC is driven by published guidelines and reflects evidence based on clinical trials and regulatory approvals. In this fast‐moving space, surgeons should be aware of the critical immunohistochemical and genomic biomarkers that drive systemic therapy decisions and anticipate when such testing will be required, both to ensure adequate sampling and to advise the pathologist when tumor material will be required for biomarker analysis. The basic approaches to and sample requirements for molecular biomarker testing will be addressed. As biomarker testing moves exclusively from advanced‐stage patients into earlier stage disease, the surgeon should be aware of the relevant markers and work with the pathologist and oncologist to ensure that this information is available to facilitate timely access to therapies not just in the advanced setting, but in consideration of neoadjuvant and adjuvant care.
Small Cell Transformation in a Patient With RET Fusion–Positive Lung Adenocarcinoma on Pralsetinib
Dimou, Anastasios , Lo, Ying‐Chun , Merrell, Kenneth W. , Halling, Kevin C. , Mansfield, Aaron S. , Mansfield, Aaron S , Merrell, Kenneth W , Lo, Ying-Chun , Dimou, Anastasios

Mayo Clinic

JCO Precision Oncology | December 21, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.22.00478 | PMID 36542817 Get It

EVALUATING IMPLEMENTATION COSTS FOR A TRANSITIONAL PALLIATIVE CARE INTERVENTION TO SUPPORT RURAL CAREGIVERS
Holland, Diane E. , Vanderboom, Catherine E., Ingram, Cory , Chun, Alice, Langan, Erica , Baer‐Benson, Henry, Kaufman, Brystana G. , Griffin, Joan M.

Mayo Clinic

Innovation in Aging | December 20, 2022 | Volume: 6 | Issue: Supplement_1 | Pages: 213-213

10.1093/geroni/igac059.850 Get It

Abstract Compared to urban caregivers, rural caregivers experience greater burdens accessing coordinated care for their loved ones during and after hospital discharge. The impact of technology-enhanced transitional palliative care (TPC) on patient and caregiver outcomes is currently being evaluated in a randomized control trial. This study evaluates resource use and health system costs of this caregiver-focused TPC intervention. Rural caregivers of hospitalized patients in Minnesota, Wisconsin, and Iowa were enrolled in an 8-week intervention consisting of video visits, conducted by a registered nurse, supplemented with phone calls and texts (n=207). Labor costs were estimated using the Bureau for Labor Statistics median hourly rate for a registered nurse and compared to a scenario analysis using a nurse practitioner or social worker wages. Hours spent conducting the visits and charting were calculated using study data. A one-way sensitivity analysis estimated resource use over a range of visits per caregiver and time per visit. Caregivers received 8.8 visits on average over the study period at 45 minutes per visit. In the base case, TPC cost $330 per caregiver facilitated by a registered nurse, compared to $281 and $489 if facilitated by a social worker or nurse practitioner, respectively. The number of visits had the greatest influence on total costs of the intervention (low of $198, high of $463). TPC is a feasible, low cost strategy to enhance caregiver support in rural areas. These results pose an opportunity to consider reimbursement mechanisms to evaluate the sustainability of transitional palliative care interventions to support caregivers.
Pharmacogenomic Study—A Pilot Study of the Effect of Pharmacogenomic Phenotypes on the Adequate Dosing of Verapamil for Migraine Prevention
Chen, Yi‐Chieh , Mandrekar, Jayawant N. , Robertson, Carrie E. , Starling, Amaal J. , Cutrer, F. Michael , Robertson, Carrie E , Chen, Yi-Chieh , Wang, Han , Chiang, Chia‐Chun

Mayo Clinic

No container title available | December 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2365333/v1 Get It

Abstract OBJECTIVE Using individual pharmacogenomic phenotypes to investigate the factors affecting the efficacy and tolerability of verapamil for migraine prevention. BACKGROUND Verapamil has a wide range of dosing in headache disorders without reliable tools to predict the optimal doses for an individual. METHODS This is a retrospective chart review examining adults with existing pharmacogenomic reports at Mayo Clinic who had used verapamil for migraine. Effects of six cytochrome P450 phenotypes on the minimum effective and maximum tolerable verapamil doses for migraine prevention were assessed. RESULTS The mean minimum effective and maximum tolerable doses for the 33 patients in final analysis were 178.2(20–320) mg and 227.9(20–480) mg. A variety of CYP2C9, CYP2D6, and CYP3A5 phenotypes were found, without significant association with the verapamil doses after adjusting for age, sex, body mass index, and smoking status. CONCLUSIONS We demonstrated a wide range of effective and tolerable verapamil doses used for migraine in a cohort with various pharmacogenomic phenotypes.
Comprehensive evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9orf72 disease
Jambeau, Mélanie, Meyer, Kevin D. , Tabet, Ricardos, Lee, Chao-Zong , Ray-Soni, Ananya, Aguilar, Corey, Savage, Kitty, Mishra, Nibha, Cavegn, Nicole, Borter, Petra, Lin, Chun-Chia , Jansen‐West, Karen , Freyermuth, Fernande, Pérez‐Berlanga, Manuela , Jiang, Xin, Daughrity, Lilian M., Pereira, João D. , Narayanan, Sarav, Gu, Yuanzheng , Dhokai, Shekhar, Dalkilic-Liddle, Isin, Maniecka, Zuzanna, Weber, Julien, McAlonis‐Downes, Melissa , Berezovski, Eugene, Zhang, Yong-Jie, Wainger, Brian J. , Kankel, Mark W. , Rushe, Mia, Höck, Christoph, Nitsch, Roger M., Cleveland, Don W. , Petrucelli, Leonard , Polymenidou, Magdalini , Lagier‐Tourenne, Clotilde , Zhang, Yong‐Jie , Zhang, Yong-Jie , Lagier-Tourenne, Clotilde , Jiang, Xin , Zhang, Yong-Jie , Hruška-Plocháň, Marián , Ray-Soni, Ananya, Mishra, Nibha, Li, Nan , Rossi, Pierre De , Daughrity, Lilian M., Workman, Michael J. , Berry, James D. , Gendron, Tania F. , Montrasio, Fabio , Grimm, Jan

Mayo Clinic

Proceedings of the National Academy of Sciences | December 1, 2022 | Volume: 119 | Issue: 49 | Pages: No page available

10.1073/pnas.2123487119 | PMID 36454749 Get It

Hexanucleotide G 4 C 2 repeat expansions in the C9orf72 gene are the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. Dipeptide repeat proteins (DPRs) generated by translation of repeat-containing RNAs show toxic effects in vivo as well as in vitro and are key targets for therapeutic intervention. We generated human antibodies that bind DPRs with high affinity and specificity. Anti-GA antibodies engaged extra- and intra-cellular poly-GA and reduced aggregate formation in a poly-GA overexpressing human cell line. However, antibody treatment in human neuronal cultures synthesizing exogenous poly-GA resulted in the formation of large extracellular immune complexes and did not affect accumulation of intracellular poly-GA aggregates. Treatment with antibodies was also shown to directly alter the morphological and biochemical properties of poly-GA and to shift poly-GA/antibody complexes to more rapidly sedimenting ones. These alterations were not observed with poly-GP and have important implications for accurate measurement of poly-GA levels including the need to evaluate all centrifugation fractions and disrupt the interaction between treatment antibodies and poly-GA by denaturation. Targeting poly-GA and poly-GP in two mouse models expressing G 4 C 2 repeats by systemic antibody delivery for up to 16 mo was well-tolerated and led to measurable brain penetration of antibodies. Long-term treatment with anti-GA antibodies produced improvement in an open-field movement test in aged C9orf72 450 mice. However, chronic administration of anti-GA antibodies in AAV-(G 4 C 2 ) 149 mice was associated with increased levels of poly-GA detected by immunoassay and did not significantly reduce poly-GA aggregates or alleviate disease progression in this model.
Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk
Sanchez, Larysa , Cheng, Mu, Cherepanov, Dasha , DerSarkissian, Maral , Stull, Dawn Marie, Hilts, Annalise, Duh, Mei Sheng , Huang, Fei, Chun, Justin, Ailawadhi, Sikander

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4308-4309

10.1182/blood-2022-156320 Get It